All In Biotech

Drug Trial Radar · NCT05441267

A Study of Cardiovascular Events iN Diabetes Plus

Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 21,296 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

21,296

Actual

Start

Mar 13, 2023

Primary completion

Aug 17, 2028

Study completion Aug 17, 2048

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Novo Nordisk A/S
First posted
Jul 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ASCEND PLUS is testing whether, for people with type 2 diabetes who have not previously had a heart attack or stroke, regularly taking a tablet called semaglutide can safely help to reduce heart attacks, strokes, mini-strokes, the need for any procedures to unblock or bypass an artery to their heart, and the chance of dying because of vascular problems.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • Semaglutide Oral TabletDrug

    Oral semaglutide 14mg daily (option to reduce to 7mg daily)

  • Placebo oral tabletDrug

    Placebo oral semaglutide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to the first occurrence of a Major Adverse Cardiovascular Events (MACE+)Time frame: Scheduled treatment period (anticipated median follow-up period of 5-years)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Service Unit and Epidemiological Studies Unit

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.